OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
$4.76
arrow_upward
+0.85%(+0.040) 1D
Oct 13, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for OPHLY...
Open
$4.78
High
$4.78
Low
$4.76
Mkt. cap
1.13T
Avg. vol.
60.13K
Volume
82.82K
52-wk high
$5.75
52-wk low
$3.81
Beta
0.21
Shares outstanding
1.50B
No. of employees
4K
Open
$4.78
High
$4.78
Low
$4.76
Mkt. cap
1.13T
Avg. vol.
60.13K
Volume
82.82K
52-wk high
$5.75
52-wk low
$3.81
Beta
0.21
Shares outstanding
1.50B
No. of employees
4K
News stories
From web sources and news partners
www.marketscreener.com
·
1 hour ago
S&P 500 index edged higher after Stockholm Stock Exchange close on Tuesday
Yahoo Finance
·
28 minutes ago
The S&P 500 Just Hit a Record High. Here's Why History Says It's Still a Smart Time to Invest.
Stocktwits
·
8 minutes ago
UNH Stock Outpaces S&P 500 In 2026, Eyes Best Year Since Pandemic — CFO Says Wall Street May Be Missing 2027 Upside
HDFC Sky
·
2 hours ago
US Stocks End Mixed as Chip Selloff Hits Nasdaq
Profile
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
About Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
CEOGyo Sagara | Gyo Sagara
Employees4.21K
Founded1717
HeadquartersOsaka, Osaka, Japan
SectorPharmaceutical industry
Websiteono-pharma.com